Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016
|
|
- Kelley Skinner
- 6 years ago
- Views:
Transcription
1 Is Universal Pediatric Lipid Screening Justified? YES Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016
2 None Disclosures
3 What is a Pediatrician? Pediatrics is the specialty of medical science concerned with the physical, mental and social health of children from birth to young adulthood. Pediatricians encompasses a broad spectrum of health services ranging from preventative health care to the diagnosis and treatment of acute and chronic diseases.
4 General Pediatrics Screening Screening healthy population Selective screening UNIVERSAL SCREENING Newborn screen Hgb/HCT Lead levels MCAT questionaire HEADSS questionaire Hearing Vision
5 Prevention Strategies 1. Primordial Prevention > Prevent the development of RISK FACTORS 2. Primary Prevention > Prevent the Disease 3. Secondary Prevention > Early disease state & prevent symptomatic manifestation 4. Tertiary Prevention > Attempt to minimize the adverse impact of the disease
6 Prevalence of Common Pediatric Diseases Disease Inheritance Prevalence PKU AR 1/14,000 1/20,000 Galactosemia AR 1/60,000 CAH AR 1/15,000 1/20,000 Congenital Hypothyroid Multifactorial 1/3000 CF AR 1/3500 Heterozygous FH AR 1/500
7 Evolution of Pediatric Lipid Guidelines National Cholesterol Education Program (NCEP), Report of the Expert Panel on Blood Cholesterol Levels in Children & Adolescents, 1992 AAP-Cholesterol in Children (Committee on Nutrition), 1998 Lipid Screening & Cardiovascular Health in Children, 2008 Lipid Research Clinic Prevalence Study 1971 NCEP 1988 NCEP 1992 AAP 1998 USPSTF 2007 AAP 2008 NLA 2011 NHLBI 2011 AAP Bright Future 2012 USPSTF
8 40 to 60% of children would be missed with dyslipidemia
9 Morbid Obesity Rates Increased
10 USPSTF Lipid Screening Recommendations Children ages 1-20 concludes that there is (I)nsufficient evidence to recommend routine screening (2016) Did not recommend: BMI screening obesity (USPSTF, 2005)
11 Universal Lipid Screening 9 to 11 years of age
12 Screening Test Non-Fasting: Non-HDLc (TC-HDL) Sensitivity (88-96%) Specificity (98%) Fasting: Lipid Panel TC, LDL, TG, HDL VLDL TG/HDL (Obesity)
13 Pediatric Lipid Studies Korean Autopsy Study Lipid Research Prevalence Study PDAY Study Bogalusa Heart Study Muscatine Study CV Risk-Young Finns Study CARDIA Study NHANEs Statin Medication Studies DISC Study: The Dietary Intervention Study in Children STRIP Study: CATCH Study
14 Atherosclerosis Begins in Childhood
15
16
17 Dietary counseling beginning in infancy is effective with results sustained into young adult life Sustained lower LDL-C, Lower SBP/DBP, less obesity and less insulin resistance
18 Lipid Risk Stratification Risk Factors Moderate Risk High Risk Family History - Premature CVD or Dyslipidemia BMI/Obesity >95 th percentile >97% percentile Hypertension No Rx Medications HDL-C <40mg/dl - Tobacco Use - Current Smoker Risk Conditions -Kawasaki with regressed coronary aneurysm -Kawasaki with current coronary aneurysm -Chronic Inflammatory Dz (SLE, JRA) -HIV Infection -Nephrotic Syndrome -Type I or II Diabetes -Heart Transplant -Chronic Kidney Dz/ESRD or post renal transplant
19 When to Consider Treatment 1. Failure 6-12 months of lifestyle management 2. Age > 10 years of age 3. LDL-C Level: LDL-C ( mg/dL): 2 high level risk factors or conditions 1 high + 2 moderate risk factor or conditions LDL-C ( mg/dL): Positive Family History 1 high risk factor/condition 2 moderate risk factors/conditions LDL-C (>190mg/dL) No additional factors required
20 Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized Controlled Trial No difference in academic performance, hormones, safety, labs JAMA. 2004;292(3):
21 Statin Medications are Safe in Pediatrics Well tolerated FDA approved > 10 years of age Side-effects rare Teratogenic
22
23
24 Conclusions Pediatricians should practice primoridal prevention Atherosclerosis begins in childhood Screening can be performed early and affect the natural course of the disease Epidemic obesity & increasing rates of morbid obesity Lipid screening can be performed Fasting or Non-fasting Effective interventions Implementation NHLBI screening guidelines are lagging Pediatricians continue to be the experts in preventative screening
25 THANK YOU!
26
27 Provider Responses
28
29 Provider Responses
30 Provider Response
31
32
33 Principles for Screening Test 1. Condition should be an important health problem 2. Should be detectable in the early stages 3. Early detection & treatment can affect the course of the disease 4. Should be an acceptable treatment 5. The test should have a high sensitivity and positive predictive value (validity & reliability) 6. The cost of screening should be economically balanced
Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNP- AC/PC, Texas Children s Hospital, Pediatric Cardiology
Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNPAC/PC, Texas Children s Hospital, Pediatric Cardiology Objectives Define pediatric dyslipidemia Describe the association between pediatric dyslipidemia
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationLearning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?
Scott J. Soifer, MD Professor and Vice Chair Department of Pediatrics University of California, San Francisco UCSF Benioff Children s Hospital Cholesterol and Lipids in Kids: It s a Matter of the Heart
More informationCommon dyslipidemia profiles in children
doernbecher children s hospital Common dyslipidemia profiles in children doernbecher Fasting lipid panel* Hypertriglyceridemia TG > 130 mg/dl LDL < 130 mg/dl Mixed dyslipidemia LDL > 130 mg/dl TG > 130
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationRole of diet in prevention and treatment of hypercholesterolaemia/hypertriglyceridaemia in children C. Hartman (IL)
ESPEN Congress Geneva 2014 NUTRITION IN PAEDIATRIC PATIENTS 2 Role of diet in prevention and treatment of hypercholesterolaemia/hypertriglyceridaemia in children C. Hartman (IL) Nutritional Treatment of
More informationBlood Pressure Measurement (children> 3 yrs)
Blood Pressure Measurement (children> 3 yrs) If initial BP elevated, repeat BP manually 2x and average, then classify Normal BP Systolic and diastolic
More informationDisclosure. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Case Disclosure
Sco$ J. Soifer, MD Professor and Vice Chair Department of Pediatrics University of California, San Francisco UCSF Benioff Children s Hospital Cholesterol and Lipids in Kids: Disclosure I have no financial
More informationDisclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
More informationManagement of dyslipidaemia in HIV infected children: rationale for treatment algorithm
Management of dyslipidaemia in HIV infected children: rationale for treatment algorithm Authors: Julie Lanigan, Lisa Cooke and Clare Stradling Date of Preparation: September 2010 Date reviewed: October
More informationAtherosclerotic cardiovascular disease (CVD) is the number
Recent Advances in Preventive Cardiology and Lifestyle Medicine Reduction of Risk for Cardiovascular Disease in Children and Adolescents Stephen R. Daniels, MD, PhD; Charlotte A. Pratt, PhD, RD; Laura
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationCardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
More informationHarms of treatment with cholesterol-lowering drugs in. children: A systematic review of the published literature
Harms of treatment with cholesterol-lowering drugs in children: A systematic review of the published literature Jonathan Haywood July 23 rd, 2010 Reader #1: Michael Steiner, MD Reader #2: Russell Harris,
More informationExpert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report
SUPPLEMENT ARTICLES Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR
More informationAtherosclerotic cardiovascular disease remains the leading
AHA Scientific Statement American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood Rae-Ellen W. Kavey, MD; Stephen R. Daniels, MD, PhD;
More informationTo Screen or Not to Screen and Other Assorted Cholesterol Questions
To Screen or Not to Screen and Other Assorted Cholesterol Questions Sarah D. de Ferranti, MD MPH Department of Cardiology Children s Hospital, Boston 6/5/10 UCSF sarah.deferranti@cardio.chboston.org Topics
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationDisclosures. Obesity and Its Challenges: Outline. Outline 5/2/2013. Lan Vu, MD Division of Pediatric Surgery Department of Surgery
Obesity and Its Challenges: Bariatric Surgery: Why or Why Not I have nothing to disclose Disclosures Lan Vu, MD Division of Pediatric Surgery Department of Surgery Outline Growing obesity epidemic Not
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More information1/14/2013 Pediatric Cardiovascular Disease and the Future of our Children Linda Alwine FNP-BC Objectives Identify the prevalence and epidemiology of h
Pediatric Cardiovascular Disease and the Future of our Children Linda Alwine FNP-BC Objectives Identify the prevalence and epidemiology of hyperlipidemia. Identify risk factors that lead to the development
More informationUnderstand obesity/overweight definition Understand medical consequences How to better evaluate and manage obese/overweight pediatric patients
Nicole Greenwood, M.D. Assistant Professor of Pediatrics LECOM Understand obesity/overweight definition Understand medical consequences How to better evaluate and manage obese/overweight pediatric patients
More informationCurrent Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations
Current Challenges in CardioMetabolic Testing Kenneth French, Director of Clinical Operations Disclosers Employee at VAP Diagnostics Laboratory Outline Cardiometabolic Disease: Current Challenges and Methodology
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationEuroPRevent Risk assessment models: what is to come? Risk Assessment Models: Applications in Clinical Practice
EuroPRevent 2010 Risk assessment models: what is to come? Risk Assessment Models: Applications in Clinical Practice G. De Backer Ghent University Ghent, Belgium May 5-8 2010, Prague Czech Republic G. De
More informationLIPID CLUB Rome, 2014
LIPID CLUB Rome, 2014 June the 6h 6th Hyperlipidaemia in FH Children Ornella Guardamagna University of Torino DICLOSURES Medpace Kowa DSMB member MSD, Pfizer, Synageva Investigator in industry funded trials
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationPREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION
PREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION Health Plan of Nevada and Sierra Health and Life suggest that health plan members get certain screening tests, exams and shots to stay healthy. This document
More informationMETABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Ana-Maria Pelin 1, Silvia Mǎtǎsaru 2 University
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationUnderstanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More information2017Adult Male Preventive Health Guidelines
2017Adult Male Preventive Health Guidelines Important Note Health Net s Preventive Health Guidelines provide Health Net members and practitioners with recommendations for preventive care services for the
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationThe Institute of Medicine January 8, 2009
Meeting the Challenges of Generating Useful Evidence and Using it Effectively in Obesity Prevention Decision-making The January 8, 2009 Promoting Healthy Weight using The Bright Futures Guidelines Joseph
More informationAdolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center
Adolescent Hypertension Roles of obesity and hyperuricemia Daniel Landau, MD Pediatrics, Soroka University Medical Center Blood Pressure Tables BP standards based on sex, age, and height provide a precise
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationLipids Testing
Previously Listed as Edit 12 190.23 - Lipids Testing Lipoproteins are a class of heterogeneous particles of varying sizes and densities containing lipid and protein. These lipoproteins include cholesterol
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationConceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.
Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management None Disclosures Arthur Agatston Conceptual Approach to CAD Risk Devereux Circulation, 1993 1 Age Obesity Family Hx Diabetes
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More information2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?
Evolving Role of Coronary CTA in Primary Cardiovascular Disease Prevention: Are We There Yet? Ron Blankstein, M.D., F.A.C.C. Co-Director, Cardiovascular Imaging Training Program Associate Physician, Preventive
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationDYSLIPIDEMIA RECOMMENDATIONS
DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol
More informationEUROPEAN SOCIETY OF CARDIOLOGY- CONGRESS 2010
EUROPEAN SOCIETY OF CARDIOLOGY- CONGRESS 2010 Addressing Risk in Children and Adolescents Laura L. Hayman, PhD, RN, FAAN University of Massachusetts Boston College of Nursing and Health Sciences Go Kids!
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationComparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, : Review
European Journal of Environment and Public Health, 2017, 1(1), 04 ISSN: 2468-1997 Comparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, 2011-2014: Review Rasaki Aranmolate
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE
ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE Professor Željko Reiner, MD, PhD,FRCP(Lond), FESC Director, University Hospital Center Zagreb School of Medicine, University of Zagreb,
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationSCHEDULE OF BENEFITS PLAN C
SCHEDULE OF BENEFITS PLAN C Effective September 1, 2016 All benefits, unless otherwise specified, are based on Usual, Customary and Reasonable (UCR) charges, or the network contracted amounts, and are
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationFigure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationNEW GUIDELINES FOR CHOLESTEROL
NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationLIPID GUIDELINES: 2015
LIPID GUIDELINES: 2015 D P Mikhailidis BSc MSc MD FCPP FCP FRSPH FFPM FRCP FRCPath Academic Head Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics) Royal Free campus University College
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationDrug therapy of high-risk lipid abnormalities, particularly
April 10, 2007 Q: 1 Q: 2 Q: 3 AHA Scientific Statement Embargoed for 4 PM EDT, Wednesday, March 21, 2007 Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents A Scientific Statement
More informationObesity Prevention and Treatment Program Primer
Obesity Prevention and Treatment Program Primer The following document is a resource guide for practice Quality Champions. Practice Quality Champions are asked to communicate the program recommendations,
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationAntipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD
Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine
More informationTusculum College. Benefit Summary. $25 Copay. $25 Copay. after Deductible. 20% after Deductible 20% after Deductible
Benefit Plan Features: Annual Deductible Benefit Summary Your Cost In-Network Individual/Family $750/$1500 Annual Out-of-Pocket Maximum Individual/Family $3500/$7000 4th Quarter Carry-over Covered Services
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationPrevention and Management Of Obesity Adolescents & Children
Prevention and Management Of Obesity Adolescents & Children The Pediatric Obesity Prevention and Treatment Toolkit is available at: https://www.optimahealth.com/providers/clinical-reference/pediatric-obesity-prevention-andtreatment-toolkit
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationMichigan Department of Health and Human Services Preventive Services Coverage Guidelines Healthy Michigan Plan
Plan The Patient Protection and Affordable Care Act have designated specific resources that identify the services required for coverage by the act. The following lists of services, CPT, and HCPCS codes
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationPreclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationEffective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.
Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could
More informationEarly and Periodic Screening, Diagnosis and Treatment (EPSDT)
Early and Periodic Screening, Diagnosis and Treatment (EPSDT) EPSDT and Bright Futures: New York NEW YORK (NY) Medicaid s EPSDT benefit provides comprehensive health care services to children under age
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More information40% minimum reduction from
160 Circulatory Disease Mortality Target: Death rates in England 1993-2006 Persons under 75 Death / 100,000 population A fall of 44% over 10 years 140 120 100 80 60 40 20 141.0 84.2 Immortality guaranteed
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More information